PubMed · 2020 · 13 citations · 20 references
Open access
MedicineBiochemistryOncologyMetastasisMolecular OncologyTumor ProgressionCancer Cell SignalingCancer GlycobiologyMalignant NeoplasmsMalignant TumorsMelanocytic TumorsMetabolic ReprogrammingCancer Cell Proliferation InhibitionCeramide MetabolismEnzymesGlycolysisMalignant Melanocytic TumorsMalignant ProgressionMelanoma ProgressionPyruvate Kinase Regulation
To investigate the role of C16:0 ceramide in melanoma metastatic behavior and glycolysis, five common long-chain ceramides (C16:0, C18:0, C20:0, C22:0, C24:0) were tested in melanocyte and melanoma cell lines by LC-MS. We then treated non-metastatic and metastatic melanoma cells with PDMP and exogenous C16:0 to explore their effects on proliferation, migration, and glycolysis. The long-chain ceramide was also analyzed by LC-MS after treatment. C16:0 ceramide showed the highest levels in melanocyte and melanoma cells, with all melanomas higher than melanocytes. PDMP inhibited malignant behavior and glycolysis in melanoma, and caused the accumulation of intracellular C16:0. Exogenous C16:0 promoted melanoma glycolysis, but not malignant behavior, and decreased intracellular C16:0. Finally, pyruvate kinase (PK), hexokinase (HK), and lactic acid dehydrogenase (LDH) activity, key enzymes in glycolysis, were altered after treatment with PDMP and exogenous C16:0.
20
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Ian R. Watson, Li Li, Peter K. Cabeceiras et al. · Cancer Research · 2014 · 169 citations · Full text
Importance of glycolysis and oxidative phosphorylation in advanced melanoma
Jonhan Ho, Michelle Barbi de Moura, Yan Lin et al. · Molecular Cancer · 2012 · 169 citations · Full text
Medicine, Cancer Biology, Oncology +17